Trial · NCT04424927
Results by group183
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 183
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 | Placebo | -1.32 | 95% Confidence Interval -1.66 to -0.98 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 | PRV-015 100 mg | -1.28 | 95% Confidence Interval -1.62 to -0.94 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 | PRV-015 300 mg | -1.21 | 95% Confidence Interval -1.55 to -0.88 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 | PRV-015 600 mg | -1.28 | 95% Confidence Interval -1.63 to -0.93 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 | Placebo | -0.77 | 95% Confidence Interval -1.15 to -0.40 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 | PRV-015 100 mg | -0.66 | 95% Confidence Interval -1.04 to -0.28 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 | PRV-015 300 mg | -1.02 | 95% Confidence Interval -1.39 to -0.64 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 | PRV-015 600 mg | -1.07 | 95% Confidence Interval -1.46 to -0.68 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 | Placebo | -0.89 | 95% Confidence Interval -1.15 to -0.63 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 | PRV-015 100 mg | -0.84 | 95% Confidence Interval -1.10 to -0.57 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 | PRV-015 300 mg | -0.88 | 95% Confidence Interval -1.14 to -0.62 | score on a scale | |
| Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 | PRV-015 600 mg | -1.05 | 95% Confidence Interval -1.32 to -0.78 | score on a scale | |
| Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 | Placebo | -0.39 | 95% Confidence Interval -3.82 to 3.03 | cells/100 epithelial cells | |
| Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 | PRV-015 100 mg | 1.54 | 95% Confidence Interval -1.99 to 5.07 | cells/100 epithelial cells | |
| Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 | PRV-015 300 mg | -4.11 | 95% Confidence Interval -7.56 to -0.66 | cells/100 epithelial cells | |
| Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 | PRV-015 600 mg | -4.53 | 95% Confidence Interval -8.13 to -0.93 | cells/100 epithelial cells | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs) | Placebo | Any TEAE | 34 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs) | PRV-015 100 mg | Any TEAE | 34 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs) | PRV-015 300 mg | Any TEAE | 36 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs) | PRV-015 600 mg | Any TEAE | 29 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04424927/results